The US Food and Drug Administration (FDA) has issued draft guidance for a new regulatory framework for drug sponsors seeking approval for targeted individualized therapies for ultra-rare diseases.
The so-called plausible mechanism framework aims to reduce hurdles for individualized medicines designed for patients with diseases so uncommon that it may
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day